| Market Cap | 18.10M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -12.02M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -10.00% |
| Sales | 9.67M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -23.00% |
| Dividend | N/A | Price/Book | 1.38 | EPS next 5Y | - | 52W High Chg | -65.00% |
| Recommedations | - | Quick Ratio | 0.76 | Shares Outstanding | 3.37M | 52W Low Chg | 6.00% |
| Insider Own | - | ROA | -62.93% | Shares Float | 25.33M | Beta | 0.50 |
| Inst Own | 3.09% | ROE | -184.98% | Shares Shorted/Prior | 4.33K/14.57K | Price | 0.83 |
| Gross Margin | 61.13% | Profit Margin | -124.24% | Avg. Volume | 103,596 | Target Price | - |
| Oper. Margin | -113.14% | Earnings Date | Aug 29 | Volume | 60,808 | Change | -1.06% |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
